Research
Hormonal
Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.
If you have obesity or overweight with related health issues, weekly semaglutide injections, combined with diet and exercise, can lead to significant weight loss (around 10%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.
StrongSupportsHIGH confidence
Метаанализ применения подкожного семаглутида 2,4 мг у пациентов с ИзМТ и ожирением без СД 2 типа показал, что по сравнению с плацебо семаглутид вызвал значительную дозозависимую потерю массы тела (средняя разница (MD): -10,09%; 95% ДИ: от -11,84 до -8,33; p<0.00001)
Why this rating
Based on cited meta-analyses.
Source
Overweight and obesity in metabolic syndrome
С. В. Недогода et al. · Russian Journal of Cardiology · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →